CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31

Celularity Inc

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Oct 20, 2026

$1.16−0.09 (-7.20%)

Close on Oct 19, 2026

Market cap: $35.15M
P/E (TTM): –
Dividend yield: –

Celularity Inc cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Depreciation & Amortization	7.30	7.92	9.32	9.44	8.82	8.17	–
Stock-Based Compensation	11	12	0	16	40	4.37	–
Deferred Income Taxes	–	–	–	0.00	0.00	-4.72	0.00
Change in Accounts Receivable	7.55	-3.97	-6.83	-3.58	-1.91	1.65	–
Change in Inventory	10	6.28	-0.87	-17	-6.42	-0.64	–
Change in Accounts Payable	3.13	9.24	8.50	-2.95	3.01	0.31	0.21
Change in Unearned Revenue	-1.09	0.24	1.53	0.43	-8.38	4.09	–
Operating Cash Flow	-13	-6.40	-39	-138	-110	-63	-1.10
Capital Expenditures	–	-0.16	-1.05	-5.24	-6.20	-28	–
Divestitures	–	–	–	–	–	15	–
Purchase of Investments	–	–	–	–	–	–	-288
Investing Cash Flow	–	0.51	-4.05	-5.24	-5.90	-13	-287
Share Repurchases	–	–	–	–	–	-0.26	–
Stock Issued	1.04	–	–	–	–	–	–
Taxes Paid on Share-Based Awards	-0.19	-0.43	-0.10	-0.13	–	–	–
Financing Cash Flow	19	6.70	24	120	99	102	289
Net Change in Cash	5.40	0.81	-19	-23	-17	26	0.89
Free Cash Flow	–	-6.56	-40	-143	-116	-91	–
Income Taxes Paid	0.05	–	–	–	–	0.01	0.65
Interest Paid	2.50	0.14	1.07	–	0.15	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, TTM

Gross margin: 5.3%
Operating margin: -321.3%
Net margin: -374.7%
Return on equity, FY2025: 627.7%

Financial strength

Current ratio: 0.09
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 0.5%

Valuation

P/E ratio: –
Price to sales: 1.85
Price to book: –
Dividend yield: –